Clinical Topics

Articles

The NHLBI recently updated recommendations in 6 key areas of asthma diagnosis, management, and treatment, marking the first update of the guidance in over 10 years.

NHLBI Updates Guidance for Asthma Diagnosis, Management, and Treatment

Use ICS monotherapy for this, not that. For asthma COPD overlap, don't use that, use this. Try these 4 questions on GINA and GOLD recommended treatments. 

Guideline-directed Therapy for Asthma & COPD: Use This, Not That 

COPD gets an early start, jury still out on nocturnal oxygen, breath test could distinguish COVID-19—scroll through these slides for concise summaries of the latest research findings.

What’s New in COPD? A Recap of 7 Key Studies for Primary Care

Exacerbations of asthma and COPD have a negative impact on disease process in both conditions. Find out what you know about guideline-recommended mitigation. 

Exacerbations in Asthma and COPD: A GINA & GOLD Guideline Quiz 

Increasing baseline FeNo levels were associated with reduced exacerbation and greater lung function improvement in dupilumab-vs-placebo-treated patients. 

Response to Dupilumab in Severe Asthma Predicted by Baseline FeNo 

Increased blood eosinophil counts and IgE levels are associated with higher exacerbation rates in patients with severe asthma, according to new research presented at ACAAI 2020. 

Increased Blood Eosinophil Counts, IgE Levels Linked to Higher Exacerbation Rates in Severe Asthma

Severe asthma affects 5% to 10% of adults with asthma. Find out what you know about diagnosis and treatment options for these patients with 5 no-nonsense questions. 

Severe Asthma: A 5-question POP Quiz 

The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype. 

Tezepelumab for Severe Asthma Meets Phase 3 Primary Endpoint 

Use of the myCOPD app after hospitalization for acute COPD exacerbation reduced subsequent exacerbations by nearly 50%, according to study authors.  

COPD Self-management App Reduces Exacerbations, Readmissions vs Usual Care 

New research presented at the American Thoracic Society virtual symposium showed the first-in-class drug reduced severe asthma exacerbation rate by 35% vs placebo. 

Pulmonology